Insmed Incorporated or Bausch Health Companies Inc.: Who Manages SG&A Costs Better?

SG&A Cost Management: Bausch vs. Insmed

__timestampBausch Health Companies Inc.Insmed Incorporated
Wednesday, January 1, 2014202630000031073000
Thursday, January 1, 2015268270000043216000
Friday, January 1, 2016281000000050679000
Sunday, January 1, 2017258200000079171000
Monday, January 1, 20182473000000168218000
Tuesday, January 1, 20192554000000210796000
Wednesday, January 1, 20202367000000203613000
Friday, January 1, 20212624000000234273000
Saturday, January 1, 20222625000000265784000
Sunday, January 1, 20232917000000344501000
Loading chart...

Data in motion

SG&A Cost Management: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Bausch Health Companies Inc. and Insmed Incorporated, two industry players, showcase contrasting approaches over the past decade. From 2014 to 2023, Bausch Health consistently reported higher SG&A expenses, peaking at nearly $2.9 billion in 2023. In contrast, Insmed's expenses grew from $31 million in 2014 to $345 million in 2023, marking a significant increase. Despite Bausch's larger scale, Insmed's expenses grew at a faster rate, highlighting its aggressive expansion strategy. This data underscores the importance of strategic cost management in sustaining growth and competitiveness. As the industry evolves, these insights offer a glimpse into how companies balance operational costs with market demands.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025